Clin Osteol 2020; 25(3): 120-127

Ukrajinská verzia FRAX pre posúdenie rizika zlomenín u žien s reumatoidnou artritídouReview articles

Povoroznyuk Vladyslav1, Grygorieva Nataliia1, Ivanik Oksana2, Bystrytska Maryna1, Dzerovych Nataliia1, Povorozniuk Vasyl1, Musiienko Anna1, Zaverukha Nataliia1
1 D. F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
2 РІ of the Lviv Regional Council "Lviv Regional Clinical Hospital", Lviv, Ukraine

V súčasnej dobe mnohé štúdie potvrdzujú zvýšené riziko zlomenín u pacientov s reumatoidnou artritídou (RA). FRAX je informatívny nástroj pre posúdenie rizika zlomenín, avšak údaje o jeho použití u pacientov s RA sú obmed­zené. Cieľom tejto štúdie bolo určiť pomocou ukrajinskej verzie FRAX 10-ročné riziko závažných osteoporotických zlomenín a zlomenín bedra u pacientok s RA. Vykonali sme prierezovú štúdiu prípadov (case-control study), ktorá skúmala 794 žien vo veku 40-89 rokov, rozdelených do dvoch skupín: 1. skupina (n = 397) -⁠ zdraví probandi bez RA, a 2. skupina (n = 397) -⁠ pacientky s diagnózou RA. Hodnotenie rizika závažných osteoporotických zlomenín a zlomenín bedra bolo vykonané nástrojom FRAX pre ukrajinskú populáciu. A to bez aj s meraním hustoty kostného minerálu (BMD -⁠ Bone Mineral Density). Táto štúdia preukázala, že pacientky s RA majú významne vyššie hodnoty FRAX (vyššie riziko) v porovnaní so zdravými subjektami, a to ako v celkovej skupine, tak aj v rôznych vekových podskupinách. U pacientok s RA bola zistená silná korelácia (r = 0,75) medzi hodnotami FRAX v oboch skupinách. Približne 40 % pacientiek s RA vyžaduje antiporotickú liečbu aj bez výsledku DXA, na základe hodnôt FRAX. 47 % vyžaduje prehodnotenie rizika zlomenín po meraní BMD. Iba 7 % pacientok vyžaduje revíziu liečby osteo­porózy po meraní BMD. Pre zníženie rizika osteoporotických zlomenín treba zvažovať všetky výše uvedené skutočnosti.

Keywords: FRAX; riziko zlomenin; pravdepodobnosť osteoporotických zlomenín v období 10 rokov; reumatoidná artritída

Received: August 10, 2020; Accepted: August 31, 2020; Published: December 11, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Povoroznyuk V, Nataliia G, Ivanik O, Bystrytska M, Nataliia D, Vasyl P, et al.. Ukrajinská verzia FRAX pre posúdenie rizika zlomenín u žien s reumatoidnou artritídou. Clinical Osteology. 2020;25(3):120-127.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sparks JA. Rheumatoid Arthritis. Ann Intern Med 2019; 170(1): ITC. 1-16. Dostupné z DOI: <http://doi/10.7326/AITC201901010>. Go to original source...
    2. Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells 2020; 9(4): pii. E880. Dostupné z DOI: <http://dx.doi.org/10.3390/cells9040880>. Go to original source...
    3. Adami G, Saag KG. Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis. Curr Rheumatol Rep 2019; 21(7): 34. Dostupné z DOI: <http://dx.doi.org/10.1007/s11926-019-0836-7>. Go to original source...
    4. Adami G, Fassio A, Rossini M et al. Osteoporosis in Rheumatic Diseases. Int J Mol Sci 2019; 20(23): 5867. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms20235867>. Go to original source...
    5. Chotiyarnwong P, McCloskey E. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 2020; 16 : 437-447. Dostupné z DOI: <http://dx.doi.org/10.1038/s41574-020-0341-0>. Go to original source...
    6. Wang Y, Hao YJ, Deng XR et al. Risk factors for bone mineral density changes in patients with rheumatoid arthritis and fracture risk assessment. Beijing Da Xue Xue Bao Yi Xue Ban 2015; 47(5): 781-786>.
    7. Xue AL, Wu SY, Jiang L et al. Bone fracture risk in patients with rheumatoid arthritis. A meta-analysis. Medicine 2017; 96(36): e6983. Dostupné z DOI: <http://dx.doi.org/10.1097/md.0000000000006983>. Go to original source...
    8. Jin S, Hsieh E, Peng L et al. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int 2018; 29(6): 1263-1275. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-018-4473-1>. Go to original source...
    9. Kanis JA, Harvey NC, Johansson H et al. A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 2020; 32 : 187-196. Dostupné z DOI: <http://dx.doi.org/10.1007/s40520-019-01432-y>. Go to original source...
    10. Kanis JA, Harvey NC, Cyrus Cooper C et al. A systematic review of intervention thresholds based on FRAX. A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 2016; 11 : 25. Dostupné z DOI: <http://dx.doi.org/10.1007/s11657-016-0278-z>. Go to original source...
    11. Povoroznyuk VV, Grygorieva NV, McCloskey et al. Application of FRAX to determine the risk of osteoporotic fractures in the Ukrainian population. International Journal of Osteoporosis and Metabolic Disorders 2018; 11(1): 7-13. Dostupné z DOI: <http://dx.doi.org/10.3923/ijom.2018.7.13>. Go to original source...
    12. Povoroznyuk VV, Grygorieva NV, Kanis JA et al. Ukrainian FRAX: criteria for diagnostics and treatment of osteoporosis. Pain Joints Spine 2019; 9(4): 9-16. Dostupné z DOI: <http://dx.doi.org/10.22141/2224-1507.9.4.2019.191921>.
    13. WHO scientific group on the assessment of osteoporosis at primary health care level. Summary Meeting Report Brussels, Belgium, 5-7 May 2004. Informace dostupné z WWW: <https://www.who.int/chp/topics/Osteoporosis.pdf>.
    14. Lai EL, Huang WN, Chen HH et al. Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases. Lupus 2019; 28(8): 945-953. Dostupné z DOI: <http://dx.doi.org/10.1177/0961203319855122>. Go to original source...
    15. Phuanudom R, Lektrakul N, Katchamart W. The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis. Clinical Rheumatology 2018; 37 : 2603-2610. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067-018-4218-8. Go to original source...
    16. Choi ST, Kwon SR, Jung JY et al. Prevalence and Fracture Risk of Osteoporosis in Patients with Rheumatoid Arthritis: A Multicenter Comparative Study of the FRAX and WHO Criteria. J Clin Med 2018; 7(12): pii. E507. Dostupné z DOI: <http://dx.doi.org/10.3390/jcm7120507>. Go to original source...
    17. Meng J, Li Y, Yuan X, Lu Y. Evaluating osteoporotic fracture risk with the Fracture Risk Assessment Tool in Chinese patients with rheumatoid arthritis. Medicine (Baltimore) 2017; 96(18): e6677. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000006677>. Go to original source...
    18. Povoroznyuk VV, Grygorieva NV, Ivanik OC. 10-year probability of major osteoporotic fractures in women with rheumatoid arthritis by the Ukrainian FRAX model. Trauma 2020; 21(2): 1-7. Dostupné z DOI: <http://dx.doi.org/10.22141/1608-1706.2.21.2020.202227>. Go to original source...
    19. Elde KD, Madsen OR. FRAX 10-yr fracture risk in rheumatoid arthritis-assessments with and without bone mineral density may lead to very different results in the individual patient. Journal of Clinical Densitometry 2019; 22(1): 31-38. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jocd.2018.10.007>. Go to original source...
    20. Broy SB, Tanner SB. FRAX(reg) Position Development Conference Members. Official Positions for FRAX® clinical regarding rheumatoid arthritis from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 2011; 14(3): 184-189. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jocd.2011.05.012>. Go to original source...
    21. Leib ES, Saag KG, Adachi JD et al; FRAX(reg) Position Development Conference Members. Official Positions for FRAX(reg) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(reg) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(reg). J Clin Densitom 2011; 14(3): 212-219. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jocd.2011.05.014>. Go to original source...
    22. Kanis JA, Johansson H, Oden A et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011; 22(3): 809-816. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-010-1524-7>. Go to original source...
    23. Cosman F, de Beur S J, LeBoff MS et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International 2014; 25(10): 2359-2381. Dostupné z DOI: <http://doi:10.1007/s00198-014-2794-2>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.